Phase 3 Brain Cancer Trial, Recruiting NCT06229483 Sponsor: Stephen Lownie Condition: Brain Cancer
Back to Brain Cancer

Phase 3 Brain Cancer Trial, Recruiting

NCT06229483
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between 18 and 80 years of age (either male or female)
  • People who are already scheduled to have a craniotomy (a type of brain surgery) to remove a tumor
  • People who have given written consent to participate, or whose legal decision-maker has given written consent on their behalf

Who may not be able to join:

  • People who have a current or past history of blood clot conditions, including deep vein thrombosis (blood clots in the veins)
  • People with a known pre-existing condition that affects blood clotting, such as hemophilia, Von Willebrand disease, or other clotting factor deficiencies
  • People with reduced kidney function below a certain level, or those currently on dialysis for kidney failure (confirm specific kidney function thresholds with the trial site)
  • People who are currently pregnant or breastfeeding
  • People with a very high body mass index (BMI of 40 or above), which is classified as Class 3 or high-risk obesity
  • People whose surgery is classified as an emergency craniotomy, or who are having a smaller or different type of skull surgery (mini craniotomy or craniectomy)
  • People who have already had an embolization procedure (a treatment that blocks blood flow to the tumor) before their surgery

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Stephen Lownie, MD, Nova Scotia Health Authority- Queen Elizabeth II HSC

Phone: 902-473-6449

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Stephen Lownie
Registry
ClinicalTrials.gov
Start date
3 April 2024
Est. completion
31 January 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Estimated intraoperative blood loss; Reoperation or disability or death due to intracranial hemorrhage within 30 days

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov